Chimeric antigen receptor T-cell therapy has improved health outcomes at a more cost-effective rate than other cancer treatments, according to a...
Myeloma NZ
Research Review: Multiple Myeloma Summit
Research Review Multiple Myeloma Summit Highlights include:Â High risk MM outcomes 5-year results for CyBorD MRD for guiding myeloma treatment...
Innovative cancer research gets a $600k leg up from Kiwi Freemasons
A New Zealand research team on the cusp of a cancer breakthrough has been gifted a significant financial boost thanks to the world's oldest...
Anti-BCMA CAR T Cell Development Continues to Evolve for Multiple Myeloma
Each of the many BCMA-targeted chimeric antigen receptor (CAR) T cells in development demonstrate a different efficacy and safety profile, and each...
‘Exciting’ but early results in trial of immunotherapy for myeloma
The 11 patients had already received treatment after treatment for their cancers, some as many as 20 different courses of therapy. Yet their...
CAR-T cell update: Therapy improves outcomes for patients with B-cell lymphoma
An international phase-2 trial of a CAR-T cell therapy—to be published on-line Dec. 1 in the New England Journal of Medicine (and presented at the...
You’re invited! Myeloma New Zealand Christmas Function
Ken Romeril, CEO Myeloma New Zealand Charitable Trust invites you to the Myeloma New Zealand Christmas Function 12 December, 5.00pm at BNZ Partners...
FDA Grants Poseida’s P-BCMA-101 RMAT Status for Treatment of Multiple Myeloma
The U.S. Food and Drug Administration (FDA) has granted P-BCMA-101, Poseida Therapeutics’ CAR T-cell therapy and lead product candidate,...
Expert Highlights Use of CAR T-Cell Therapy in DLBCL
There has been activity with chimeric antigen receptor (CAR) T cells in patients with relapsed diffuse large B-cell lymphoma (DLBCL),...
CAR T studies highlight Abramson Cancer Center research at ASH Annual Meeting
From better-understanding how to improve response rates in multiple myeloma patients to identifying why some patients with other types of cancer are...
Research Review: Multiple Myeloma – Issue 28
Issue 28 of Multiple Myeloma Research Review. Highlights include:Â Elotuzumab monotherapy for smouldering MM Thereapetuc vulnerability of MM to...
Registry could be ‘invaluable’ for tracking long-term CAR T-cell therapy outcomes
The Center for International Blood and Marrow Transplant Research, through an alliance with Novartis, aims to track the long-term outcomes of...